Novo Nordisk | driving change to defeat serious chronic diseases
6 days ago · Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other …
Who we are - Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in discovering and developing treatment for serious chronic disease, like diabetes …
Our heritage | Novo Nordisk | Driving change
Our history spans a century and it all began with two small Danish companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. After hearing of the discovery of …
Our products - Novo Nordisk
Overview of Novo Nordisk pharmaceutical products within diabetes, obesity, haemophilia, human growth hormone and hormone replacement therapy.
Latest news - Novo Nordisk
Dec 20, 2024 · Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Careers - Novo Nordisk
At Novo Nordisk, you will have the opportunity to build a life-changing career in a global business environment. Join us and make a difference.
Contact Novo Nordisk - How can we help you?
Do you need to get in touch with us? See your options here. Reach out to your local Novo Nordisk office or call our corporate headquarters. Tel: +45 4444 8888, Novo Allé, 2880 Bagsvaerd, …
Our medicines | Diabetes medications | Obesity medication - Novo …
In some cases, healthcare professionals and patients can visit local Novo Nordisk websites to find out more about our medicines. Please note that in some countries we are not allowed to …
Healthcare professionals | Novo Nordisk | Driving Change
Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or …
News Details - Novo Nordisk
May 13, 2024 · Contingent on regulatory interactions, Novo Nordisk aims to submit Mim8 for the first regulatory approval towards the end of 2024. Data from the phase 3 FRONTIER …